Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Nov 2016 | FROM EXTERNAL EXPERTS

An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function

Lee, J.H. et al. American Journal of Translational Research

Sep 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway

Yu, Y. et al. International Immunopharmacology

Jan 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways

Xu, P. et al. Toxicology and Applied Pharmacology

Nov 2015 | FROM EXTERNAL EXPERTS

Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Zhang, H., Yang, L. Frontiers in Endocrinology

Nov 2014 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets

Fisher, F.M. et al. Gastroenterology

Nov 2009 | FROM EXTERNAL EXPERTS

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects

Xu, J. et al. American Journal of Physiology. Endocrinology and Metabolism

Feb 2007 | FROM EXTERNAL EXPERTS

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21

Kharitonenkov, A. et al. Endocrinology

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline